News

Inhibiting cGAS Enzyme May Reduce Autoimmune Responses, Mouse Study Shows

Inhibition of a natural enzyme that works as a sensor for virus and bacteria invasions may reduce inflammation associated with autoimmune diseases, including systemic lupus erythematosus, according to a recent study. The findings, reported in the study “Small molecule inhibition of cGAS reduces interferon expression in primary macrophages…

LFA Appoints New Chair of Medical-Scientific Advisory Council

Karen H. Costenbader, MD, is the new chairwoman of the medical-scientific advisory council of the Lupus Foundation of America (LFA). Chairman of the LFA’s national board of directors, Conrad Gehrmann, announced the appointment earlier this week. Costenbader will lead the multi-disciplinary group of lupus experts to address unmet needs…

Rituxan Could Be Alternative Therapy in Patients with Neurological Issues, Case Report Indicates

Rituxan (rituximab) could be a valid alternative to standard of care in systemic lupus erythematosus (SLE) patients with neurological and psychiatric manifestations, a new Italian case report shows. The research, “Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to standard of care,” was published in…

New Guidelines Aim to Improve Diagnosis, Treatment in the UK

The United Kingdom’s first set of guidelines for care of patients with systemic lupus erythematosus (SLE) has been published by researchers at the University of Birmingham. The guidelines produced by the British Society for Rheumatology were published in the journal Rheumatology. Produced for a range of healthcare…

Amgen’s AMG 811 Fails to Improve Lupus Outcomes in Phase 1 Trial

Patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN) showed no clinical benefit when treated with Amgen‘s investigative anti-interferon-gamma antibody, AMG 811, in a Phase 1b  (NCT00818948) clinical trial. Some indicators of the disease dropped in response to the treatment, but less so in…